Celcuity (CELC)'s Clinical Success and M&A Potential Underpin Wolfe Research’s Bullish View
Celcuity Inc. (NASDAQ:CELC) is among the hottest SMID-cap stocks so far in 2025.
Celcuity Inc. (CELC)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 7,915,792 | $391,040,125 | +46% | 2.83% |
| 2. | Perceptive Advisors Joseph Edelman | 2,956,319 | $146,042,159 | +82% | 4.22% |
| 3. | Soleus Capital Guy Levy | 1,178,860 | $58,235,684 | -61% | 2.93% |
| 4. | Tang Capital Management Kevin C. Tang | 1,150,000 | $56,810,000 | 2.19% | |
| 5. | 30,750,000 | $40,905,126 | 0.3% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $58.02 | 4,212 | $244,395.40 | 7,211,484 | 2025-09-08 | Filing | |
| $58.02 | 388 | $22,513.16 | 704,308 | 2025-09-08 | Filing | |
| $56.22 | 151,524 | $8,518,679.28 | 7,207,272 | 2025-09-08 | Filing | |
| $56.22 | 13,976 | $785,730.72 | 703,920 | 2025-09-08 | Filing | |
| $10.32 | 10,000 | $103,187.00 | 10,250 | 2023-05-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $106.04 | 1,510 | $160,113.30 | 6,760 | 2025-12-05 | Filing | |
| $105.34 | 1,490 | $156,956.30 | 8,270 | 2025-12-05 | Filing | |
| $98.13 | 1,100 | $107,948.39 | 7,260 | 2025-12-01 | Filing | |
| $100.00 | 15,000 | $1,500,016.50 | 110,000 | 2025-11-21 | Filing | |
| $96.73 | 3,900 | $377,254.80 | 7,260 | 2025-11-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,246,447 | $110,974,482 | 0% | |
| 2. | 2,144,261 | $105,926,493 | 5.81% | |
| 3. | 2,059,047 | $101,716,921 | 0% | |
| 4. | 1,512,852 | $74,734,911 | 0% | |
| 5. | 42,750,000 | $57,110,965 | 0.38% |
News See All
10 Hottest SMID-Cap Stocks So Far In 2025
SMID-caps, or Small- and mid-cap stocks, are often overlooked segments of the market.
Celcuity Inc. (NASDAQ:CELC) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity Third Quarter 2025 Financial Results Webcast and Conference Call. At this time, all lines are in listen-only mode.
Celcuity (CELC) Hits Fresh Record High on Stellar Breast Cancer Drug Trial Result
This followed announcements that its drug candidate—gedatolisib, in combination with two other drugs (called the triplet)—showed a marked 76 percent reduction in the disease progression of enrolled...
Celcuity Inc. (CELC)’s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review
Celcuity Inc. (NASDAQ:CELC) is a clinical-stage biotechnology company developing targeted oncology therapies, with a focus on solid tumors such as advanced breast cancer.
12 Best Performing Healthcare Stocks to Buy Right Now
Spending on healthcare in the US is predicted to hit $5.3 trillion this year, making it one of the largest in the world.
Celcuity Inc. (NASDAQ:CELC) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity Second Quarter 2025 Financial Results Webcast and Conference Call.
Celcuity (CELC) Skyrockets 167% on Breast Cancer Treatment Trial
In a statement on Monday, Celcuity Inc. (NASDAQ:CELC) said it achieved positive topline results from the phase 3 clinical study of gedatolisib combined with palbociclib and fulvestrant—an experimental...
Celcuity Inc. (NASDAQ:CELC) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity First Quarter 2025 Financial Results Webcast Conference Call. At this time all lines are in listen-only mode.
Celcuity Inc. (NASDAQ:CELC) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity Fourth Quarter and Full Year 2024 Financial Results Webcast Conference Call.
Hedge Fund Resource Center Billionaire Hedge Funds
